Catathrenia under sodium oxybate in narcolepsy with cataplexy
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Purpose This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep.Methods Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects.Results At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA.Conclusions Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Though current data is mixed regarding this possibility,992–995”
From International Consensus Statement on Obstructive Sleep Apnea (2023) · cites this paper as [993]
Citations
Cites
The International Classification of Sleep Disorders: Diagnostic and Coding Manual
Daroff, R. B. (1991) · Neurology · doi:10.1212/wnl.41.1.160 · Cited by 5,014
Wang, Y. G., Swick, T. J., Carter, L. P., Thorpy, M. J., & Benowitz, N. L. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27549 · Cited by 271 · cited 2×
“Several lethal toxicity cases associated with SO use have been reported [9, 10], leading to a wide debate and several warnings recommending a periodical evaluation of respiratory function in SO-treated patients [11–15].”
BackgroundSelf-citationLaborit, H. (1964) · International Journal of Neuropharmacology · doi:10.1016/0028-3908(64)90074-7 · Cited by 251 · cited 1×
“Studies in animals and humans showed that, under SO at hypnotic doses, respiratory brainstem nuclei are released from cortical control to display some instability, with a slowing and deepening of respiration [ 31 ].”
BackgroundTreatment of Narcolepsy with γ-Hydroxybutyrate. A Review of Clinical and Sleep Laboratory Findings
Mamelak, M., Scharf, M. B., & Woods, M. (1986) · Sleep · doi:10.1093/sleep/9.1.285 · Cited by 231 · cited 2×
“A large study in NC patients under SO did not report worsening in breathing patterns after 9 years of follow-up [4]; no worsening was reported in a patient with NC and central apneas [17], while an improvement was documented in a patient with concomitant NC and OSA complying with nCPAP [32].”
BackgroundThe Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate
Broughton, R., & Mamelak, M. (1979) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100119304 · Cited by 163
Obstructive sleep apnea in narcolepsy
Sansa, G., Iranzo, A., & Santamaria, J. (2010) · Sleep Medicine · doi:10.1016/j.sleep.2009.02.009 · Cited by 140 · cited 2×
“The present study monitored NC patients starting SO treatment for side effects and adverse events and, considering NC a potential risk for a co-morbid obstructive sleep apnea (OSA) [20, 21], also overnight polysomnography (PSG) at baseline and during follow-up was performed.”
BackgroundVienne, J., Bettler, B., Franken, P., & Tafti, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3145-10.2010 · Cited by 112 · cited 1×
“SO acts mainly through GABA receptor B [7, 8].”
BackgroundCatathrenia (nocturnal groaning): A new type of parasomnia
Vetrugno, R., Provini, F., Plazzi, G., Vignatelli, L., Lugaresi, E., & Montagna, P. (2001) · Neurology · doi:10.1212/wnl.56.5.681 · Cited by 112 · cited 4×
“No striking prevalence in REM sleep was observed [24, 25, 27, 29], but rather a distribution in both REM and NREM sleep with a clear prevalence in NREM sleep [28].”
BackgroundResultInfluentialSelf-citationNocturnal aspects of narcolepsy with cataplexy
Plazzi, G., Serra, L., & Ferri, R. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.08.010 · Cited by 93 · cited 1×
“This tetrad is often accompanied by disrupted nocturnal sleep resulting in fragmentation and potentially reduced percentages of slow wave sleep (SWS) [2].”
BackgroundSelf-citationOff-Label Treatment of Severe Childhood Narcolepsy-Cataplexy With Sodium Oxybate
Murali, H., & Kotagal, S. (2006) · Sleep · doi:10.1093/sleep/29.8.1025 · Cited by 89 · cited 1×
“Each adult (≥18 years old) patient started the SO treatment with a dose of 2 g+2 g (at bedtime and 3 h later); each child (<18 years old) started with a dose of 1 g+1 g [23].”
MethodChokroverty, S. (1986) · Sleep · doi:10.1093/sleep/9.1.250 · Cited by 84 · cited 2×
“The present study monitored NC patients starting SO treatment for side effects and adverse events and, considering NC a potential risk for a co-morbid obstructive sleep apnea (OSA) [20, 21], also overnight polysomnography (PSG) at baseline and during follow-up was performed.”
BackgroundVocalization during episodes of prolonged expiration: a parasomnia related to REM sleep
Pevernagie, D., Boon, P., Mariman, A., Verhaeghen, D., & PAUWELS, R. A. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00039-3 · Cited by 83 · cited 3×
“onset with a large prevalence in the last third of the night [24, 25 , 27].”
BackgroundResultInfluentialNarcolepsy: Action of Two γ-Aminobutyric Acid Type B Agonists, Baclofen and Sodium Oxybate
Huang, Y., & Guilleminault, C. (2009) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2009.02.008 · Cited by 80 · cited 1×
“SO acts mainly through GABA receptor B [7, 8].”
BackgroundGeorge, C. F., Feldman, N. T., Inhaber, N., Steininger, T. L., Grzeschik, S. M., Lai, C., & Zheng, Y. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.06.006 · Cited by 76 · cited 2×
“studies, obstructive sleep apnea syndrome (OSAS) patients under SO treatment did not show any significant changein the AHI or oxygen saturation when compared to the baseline, but they showed a significant relative increase in central apneas [13, 18] with possible significant oxygen desaturation leading to SO discontin…”
BackgroundCatathrenia: Parasomnia or Uncommon Feature of Sleep Disordered Breathing?
Guilleminault, C., Hagen, C. C., & Khaja, A. M. (2008) · Sleep · doi:10.1093/sleep/31.1.132 · Cited by 76 · cited 1×
“No striking prevalence in REM sleep was observed [24, 25, 27, 29], but rather a distribution in both REM and NREM sleep with a clear prevalence in NREM sleep [ 28 ].”
BackgroundBlack, J. E., Pardi, D., Hornfeldt, C. S., & Inhaber, N. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.05.004 · Cited by 66 · cited 1×
“We propose that this discrepancy might be ascribed to the SO effects on sleep structure [ 6 ].”
BackgroundThree deaths associated with use of Xyrem®
Zvosec, D. L., Smith, S. W., & Hall, B. J. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.01.005 · Cited by 66 · cited 2×
“The effects of therapeutic SO doses on respiratory functions remain controversial, and warnings about its use have been published [9–11].”
Background‘Nocturnal groaning’: just a sound or parasomnia?
Oldani, A., Manconi, M., Zucconi, M., Castronovo, V., & Ferini‐Strambi, L. (2005) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2005.00460.x · Cited by 57 · cited 1×
“There is an ongoing debate on its nature, whether it is a parasomnia or an uncommon feature of SRBD [24–28].”
BackgroundCatathrenia (nocturnal groaning): an abnormal respiratory pattern during sleep
Vetrugno, R., Lugaresi, E., Plazzi, G., Provini, F., D’Angelo, R., & Montagna, P. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01954.x · Cited by 47 · cited 6×
“There is an ongoing debate on its nature, whether it is a parasomnia or an uncommon feature of SRBD [24–28].”
BackgroundResultInfluentialSelf-citationFeldman, N. T. (2009) · Sleep And Breathing · doi:10.1007/s11325-009-0283-1 · Cited by 43 · cited 2×
“Several lethal toxicity cases associated with SO use have been reported [9, 10], leading to a wide debate and several warnings recommending a periodical evaluation of respiratory function in SO-treated patients [11–15].”
BackgroundMethodEffects of Enhancing Slow-Wave Sleep by Gamma-Hydroxybutyrate on Obstructive Sleep Apnea
Sériès, F., Sériès, I., & Cormier, Y. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1378 · Cited by 43
Pinna Cues Determine Orienting Response Modes to Synchronous Sounds in Elevation
Bremen, P., van Wanrooij, M. M., & Opstal, A. J. V. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2982-09.2010 · Cited by 40
A Multi‐Drug Intoxication Fatality Involving Xyrem® (GHB)
Akins, B. E., Miranda, E. J., Lacy, J. M., & Logan, B. K. (2009) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2008.00965.x · Cited by 39 · cited 1×
“SO acts mainly through GABA receptor B [7, 8]. Several lethal toxicity cases associated with SO use have been reported [ 9 , 10], leading to a wide debate and several warnings recommending a periodical evaluation of respiratory function in SO-treated patients [11–15].”
BackgroundSeeck-Hirschner, M., Baier, P. C., von Freier, A., Aldenhoff, J., & Göder, R. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2007.11.018 · Cited by 34 · cited 2×
“Worsening of sleeprelated breathing disturbances in narcolepsy patients with mild OSA under SO, suggesting SO discontinuation and/or nCPAP treatment, has also been reported [16].”
BackgroundArousals in nocturnal groaning
Příhodová, I., Šonka, K., Kemlink, D., Volná, J., & Nevšímalová, S. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.09.019 · Cited by 29 · cited 1×
“An arousal could precede the episode, as reported elsewhere [30].”
ResultSodium oxybate is an effective and safe treatment for narcolepsy
Lammers, G. J., Bassetti, C. L., Billiard, M. M., Black, J. E., Broughton, R., Dauvilliers, Y. A., Ferini‐Strambi, L., García-Borreguero, D., Goswami, M., Högl, B., et al. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.08.003 · Cited by 29 · cited 1×
“From our perspective, a close follow-up of SO treatment in NC patients, allowing prompt management of side effects, may reduce the incidence of withdrawal and thereby avoid discontinuation of an effective and safe treatment option [5, 32, 33].”
BackgroundSelf-citationYoss, R. E. (1960) · Archives of Internal Medicine · doi:10.1001/archinte.1960.03820020008003 · Cited by 28
Long-Term Follow-Up of Patients With Narcolepsy-Cataplexy Treated With Sodium Oxybate (Xyrem)
Alshaikh, M. K., Gacuan, D., George, S., Sharif, M. M., & BaHammam, A. S. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318203d415 · Cited by 25 · cited 4×
“Compulsory nCPAP compliance in OSAS patients under SO has been also recommended [14, 32].”
BackgroundInfluentialMamelak, M., & Webster, P. (1981) · SLEEP · doi:10.1093/sleep/4.1.105 · Cited by 22 · cited 2×
“A large study in NC patients under SO did not report worsening in breathing patterns after 9 years of follow-up [4]; no worsening was reported in a patient with NC and central apneas [17], while an improvement was documented in a patient with concomitant NC and OSA complying with nCPAP [32].”
BackgroundResultSodium oxybate for the treatment of narcolepsy
Thorpy, M. J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.2.329 · Cited by 18 · cited 2×
“Sodium oxybate (SO) is a first-line treatment in NC patients, which improves nocturnal sleep and significantly decreases cataplexy [3–6].”
BackgroundSelf-citationRamar, K., Olson, E. J., & Morgenthaler, T. I. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2007.08.011 · Cited by 17
Xyrem® safety: The debate continues
Feldman, N. T. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.02.002 · Cited by 12 · cited 2×
“The effects of therapeutic SO doses on respiratory functions remain controversial, and warnings about its use have been published [9–11].”
BackgroundUse of sodium oxybate (Xyrem®) in patients with dual diagnosis of narcolepsy and sleep apnea
Kovačević-Ristanović, R., & Kuźniar, T. J. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.09.001 · Cited by 8 · cited 2×
“Compulsory nCPAP compliance in OSAS patients under SO has been also recommended [14, 32].”
BackgroundOrtega-Albás, J. J., López-Bernabé, R., Diaz, J. R., & Serrano, A. L. (2009) · Sleep And Breathing · doi:10.1007/s11325-009-0316-9 · Cited by 7 · cited 1×
“However, to date, prospective studies on the effects of SO on sleep-disordered breathing are limited, and findings remain contradictory [17–19].”
Result
Cited by
International Consensus Statement on Obstructive Sleep Apnea
Chang, J. L., Goldberg, A. N., Alt, J. A., Mohammed, A., Ashbrook, L., Auckley, D., Ayappa, I., Bakhtiar, H., Barrera, J. E., Bartley, B. L., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23079 · Cited by 350
A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes
Mignot, E. J. M. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0150-9 · Cited by 210
“More rarely, parasomnias, such as sleep-walking, night eating (also common in untreated patients) or expiratory groaning [61, 62] can occur, and these side effects are also dose-dependent.”
BackgroundEuropean guideline and expert statements on the management of narcolepsy in adults and children
Bassetti, C. L. A., Kallweit, U., Vignatelli, L., Plazzi, G., Lecendreux, M., Baldin, E., Dolenc‐Groselj, L., Jennum, P., Khatami, R., Manconi, M., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14888 · Cited by 165
Self-citationEuropean guideline and expert statements on the management of narcolepsy in adults and children
Bassetti, C. L., Kallweit, U., Vignatelli, L., Plazzi, G., Lecendreux, M., Baldin, E., Dolenc‐Grošelj, L., Jennum, P., Khatami, R., Manconi, M., et al. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13387 · Cited by 132
Self-citationThe clinical spectrum of childhood narcolepsy
Postiglione, E., Antelmi, E., Pizza, F., Lecendreux, M., Dauvilliers, Y. A., & Plazzi, G. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.04.003 · Cited by 119
Self-citation
Metadata
- Authors
- Poli, F., Ricotta, L., Vandi, S., Franceschini, C., Pizza, F., Palaia, V., Moghadam, K. K., Banal, D., Vetrugno, R., Thorpy, M. J., & Plazzi, G.
- Affiliations
- University of Bologna (IT)
- Azienda-Unita' Sanitaria Locale Di Cesena (IT)
- Montefiore Medical Center (US)
- Corresponding author
- Plazzi, Giuseppe
- ORCID
- Venue
- Sleep and Breathing
- Published
- 2011-04-12
- Volume
- 16
- Issue
- 2
- Pages
- 427-434
- ISSN
- 1520-9512 (ISSN-L)
- 1522-1709
- OpenAlex
- W1978560955
- Cited by
- 34
- References
- 34
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 3
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Sleep And Breathing (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- Jazz Pharmaceuticals
- UCB Pharma
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- catathrenia, sodium oxybate, narcolepsy type 1, adverse drug reactions, obstructive sleep apnea, sleep-disordered breathing, parasomnias, nasal continuous positive airway pressure, polysomnography
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Cataplexy, Central Nervous System Depressants, Child, Combined Modality Therapy, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Narcolepsy, Patient Compliance, Sodium Oxybate, Comorbidity, Polysomnography, Sleep Apnea, Obstructive, Parasomnias, Continuous Positive Airway Pressure, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.